References
- Diovan (Valsartan): Novartis Pharmaceuticals, NJ, USA, product information. In: Physician’s desk reference, 2002, pp.2337–8
- Criscione L, Bradley WA, Buhlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc drug rev 1995;13: 230–50
- Kalbag J, Prasad P, Redaliew E. Plasma concentrations and antihypertensive effect of 10 to 160 mg doses of valsartan in hypertensive patients. Pharm Res 1994;11(Suppl):S367 [abstract]
- Colussi DM, Parisot C, Rossolino ML, et al. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol 1997;37:214–21
- Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997;62:272–8
- Mauro VF. Simvastatin: a review of its pharmacology and clinical use. DICP 1991;25:257–64
- Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993;24:195–202
- Vickers S, Duncan CA, Vyas KP, et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990;18:476–83
- Zocor (simvastatin): Merck & Co., Inc., NJ, USA, product information. In: Physician’s desk reference, 2002, pp.2219–23
- Internal report – CGP 48933 – assessment of dose proportionality of valsartan following single oral doses of 80, 160 and 320 mg in healthy subjects, 1995 [data on file]
- Bedigian MP, O’Connor R, Prasad PP, et al. Valsartan does not interfere with the pharmacokinetics of phenytoin. AAPS pharmsci 1999;1 [abstract 3068]
- Kyrklund C, Backman JT, Kivistö KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000;68:592–97
- Simard C, O’Hara GE, Prévost J, et al. Study of the drug-drug interaction between simvastatin and cisapride in man. Eur J Clin Pharmacol 2001;57:229–34
- Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25:1191–9
- Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization. Drug Metab Dispos 2002;30:505–12
- Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50: 209–15
- Pelkonen O, Taavitsainen P, Kiukaanniemi K. In vitro inhibition of human hepatic P450 enzymes by four angiotensin II receptor antagonist. J Hum Hypertens 1999;13:S40 [abstract O55]
- Lilja JJ, Kivisto KT, Neuvoven PJ. Grapefruit juice-simvastatin interaction: effect of serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477–83
- Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177–82
- Schmidt EK, Antonin KH, Flesch G, et al. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol 1998;53:451–8